Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.61
-0.0100-0.62%
Post-market: 1.60-0.0095-0.59%18:52 EDT
Volume:6.74M
Turnover:9.67M
Market Cap:36.49M
PE:-0.12
High:1.61
Open:1.50
Low:1.24
Close:1.62
52wk High:10.99
52wk Low:1.24
Shares:22.66M
Float Shares:15.77M
Volume Ratio:8.47
T/O Rate:42.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.11
PE(LYR):-0.09

Loading ...

Karyopharm Therapeutics - Enters Forbearance Agreement and Waiver on Sept 10, 2026 - SEC Filing

Reuters
·
Yesterday

Karyopharm Therapeutics - Did not Pay $15.80 Mln Principal Installment Due Sept 10, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Karyopharm Therapeutics - to Pay Fees in Shares of Newly Created Preferred Stock - SEC Filing

THOMSON REUTERS
·
Yesterday

Karyopharm Therapeutics - Does not Expect to Pay Cash Interest Due Sept 30, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Karyopharm Enters Creditor Forbearance Pact After Missing USD 15.8 Million Term-Loan Payment

Reuters
·
Yesterday

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

Karyopharm Grants 1,850 Inducement RSUs to Two New Hires

Reuters
·
Sep 02

Karyopharm submits sNDA to FDA for XPOVIO

TIPRANKS
·
Aug 31

Karyopharm Seeks FDA Accelerated Approval for Xpovio-Ruxolitinib Combo in Myelofibrosis

Reuters
·
Aug 31

Karyopharm Submits Supplemental New Drug Application to the FDA for Xpovio® (Selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

THOMSON REUTERS
·
Aug 31

Karyopharm Therapeutics - Expects FDA Decision on Snda Filing Acceptance in Q4 2026

THOMSON REUTERS
·
Aug 31

Karyopharm Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Karyopharm Q2 Revenue Falls as License Revenue Drops; Expects Funds to Last into September

Reuters
·
Aug 13

Karyopharm Q2 FY26 Net Loss Widens to $67 Million; Revenue Falls 11.85% to $33.4 Million

Reuters
·
Aug 13

Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate

Benzinga Earnings
·
Aug 13

Karyopharm Therapeutics Q2 Net Income USD -67.023 Million

Reuters
·
Aug 13

Karyopharm Therapeutics Q2 Operating Expenses USD 55.958 Million

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Actively Evaluating Financing Opportunities and Strategic Alternatives with Centerview Partners

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Expects Existing Liquidity to Fund Operations into September 2026

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Planned August Snda Submission for Selinexor Plus Ruxolitinib in Myelofibrosis Remains on Track

THOMSON REUTERS
·
Aug 13